Revolution Medicines Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	-	-	11.58	35.38	29.39	42.98
Revenue Growth (YoY)	-	-	-67.27%	20.38%	-31.62%	-14.10%
Cost of Revenue	880.49	592.23	411.24	253.07	186.95	132.25
Gross Profit	-880.49	-592.23	-399.66	-217.69	-157.56	-89.27
Selling, General & Admin	156.57	97.3	62.02	40.59	30.45	21.43
Operating Expenses	156.57	97.3	62.02	40.59	30.45	21.43
Operating Income	-1,037	-689.52	-461.69	-258.28	-188.01	-110.7
Interest Expense	-12.3	-	-0.3	-	-0.01	-0.07
Interest & Investment Income	90.63	86.88	47.48	9.15	0.93	2.24
Other Non Operating Income (Expenses)	-3.01	1.8	0.12	-	-	-
EBT Excluding Unusual Items	-961.73	-600.85	-414.39	-249.13	-187.09	-108.53
Merger & Restructuring Charges	-	-	-25.5	-	-	-
Pretax Income	-961.73	-600.85	-439.89	-249.13	-187.09	-108.53
Income Tax Expense	-0.75	-0.75	-3.52	-0.42	-	-0.37
Net Income	-960.98	-600.09	-436.37	-248.71	-187.09	-108.16
Preferred Dividends & Other Adjustments	-	-	-	-	-	2.22
Net Income to Common	-960.98	-600.09	-436.37	-248.71	-187.09	-110.38
Shares Outstanding (Basic)	185	168	113	81	73	55
Shares Outstanding (Diluted)	185	168	113	81	73	55
Shares Change (YoY)	15.98%	48.24%	40.34%	10.74%	32.68%	1879.16%
EPS (Basic)	-5.19	-3.58	-3.86	-3.08	-2.57	-2.01
EPS (Diluted)	-5.19	-3.58	-3.86	-3.08	-2.57	-2.01
Free Cash Flow	-777.08	-567.74	-358.3	-235.22	-153.71	-103
Free Cash Flow Per Share	-4.20	-3.38	-3.17	-2.92	-2.11	-1.88
Gross Margin	-	-	-	-	-	-207.68%
Operating Margin	-	-	-3986.92%	-730.01%	-639.70%	-257.54%
Profit Margin	-	-	-3768.28%	-702.95%	-636.58%	-256.80%
Free Cash Flow Margin	-	-	-3094.14%	-664.83%	-522.99%	-239.62%
EBITDA	-1,030	-683	-456.68	-254.34	-184.96	-108.12
EBITDA Margin	-	-	-	-	-	-251.54%
D&A For EBITDA	7.22	6.53	5.01	3.94	3.05	2.58
EBIT	-1,037	-689.52	-461.69	-258.28	-188.01	-110.7
EBIT Margin	-	-	-	-	-	-257.54%
Revenue as Reported	-	-	11.58	35.38	29.39	42.98

Source: S&P Global Market Intelligence. Standard template. Financial Sources.